Shares of Tonix Pharmaceuticals are up over 35% in 2014 because investors are finally starting to appreciate the company's story, says Tonix CEO Dr. Seth Lederman. The biotech, which raised $43 million in a January secondary, is working on prescription medicines for post traumatic stress syndrome, headaches and fibromyalgia. Lederman is confident he will have top line data on the fibromyalgia treatment in the second half of 2014, adding that it should be a speedier trial process since this is a reformulation of an already approved, older drug.

Disclosure: TheStreet's editorial policy prohibits staff editors and reporters from holding positions in any individual stocks.

If you liked this article you might like

Mirati Skyrockets On Positive Data - Biotech Movers

5 Stocks Poised for Major Breakouts

Can You Catch These 6 Stocks Under $10 on Their Way Up?

6 Stocks Under $10 Making Big Moves Higher

Trade These 5 Breakout Stocks for Big Gains